AIM-LO

🚀 Introducing AIM-LO (ASCVD Identification and Management of Lipid Lowering Therapy) – an AI-driven initiative for Canadian specialists, leveraging data held in EMRs to identify high-risk patients with dyslipidemia whose LDL-C exceeds 1.8 mmol/L as per the 2021 CCS Guideline recommendations. Our Scientific Committee, composed of Canadian experts and guideline authors, conceptualized this program to help their peers optimize patient treatment while minimizing any burdens. Join us in reshaping the future of healthcare. #DoYouAimLo #CardioCare🏥📊